WO2021199850A1 - 酸化ストレス抑制剤及び抗酸化剤 - Google Patents
酸化ストレス抑制剤及び抗酸化剤 Download PDFInfo
- Publication number
- WO2021199850A1 WO2021199850A1 PCT/JP2021/007917 JP2021007917W WO2021199850A1 WO 2021199850 A1 WO2021199850 A1 WO 2021199850A1 JP 2021007917 W JP2021007917 W JP 2021007917W WO 2021199850 A1 WO2021199850 A1 WO 2021199850A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silicon
- oxidative stress
- hydrogen
- particles
- fine particles
- Prior art date
Links
- 230000036542 oxidative stress Effects 0.000 title claims abstract description 138
- 239000003112 inhibitor Substances 0.000 title claims abstract description 126
- 239000003963 antioxidant agent Substances 0.000 title claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 153
- 239000001257 hydrogen Substances 0.000 claims abstract description 153
- 239000011856 silicon-based particle Substances 0.000 claims abstract description 132
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 107
- 239000010703 silicon Substances 0.000 claims description 107
- 229910052710 silicon Inorganic materials 0.000 claims description 107
- 239000010419 fine particle Substances 0.000 claims description 88
- 230000003078 antioxidant effect Effects 0.000 claims description 43
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 230000006872 improvement Effects 0.000 claims description 15
- 206010019133 Hangover Diseases 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 239000013589 supplement Substances 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010010774 Constipation Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 7
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 139
- 230000000694 effects Effects 0.000 abstract description 21
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 230000003028 elevating effect Effects 0.000 abstract 1
- 238000006257 total synthesis reaction Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 229910052751 metal Inorganic materials 0.000 description 48
- 239000002184 metal Substances 0.000 description 45
- 235000006708 antioxidants Nutrition 0.000 description 41
- 230000004048 modification Effects 0.000 description 30
- 238000012986 modification Methods 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 28
- 239000007788 liquid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 230000037406 food intake Effects 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 230000008093 supporting effect Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 235000013373 food additive Nutrition 0.000 description 9
- 239000002778 food additive Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 210000000628 antibody-producing cell Anatomy 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229910052814 silicon oxide Inorganic materials 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 235000012239 silicon dioxide Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 239000005543 nano-size silicon particle Substances 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 6
- 210000004180 plasmocyte Anatomy 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000002407 reforming Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 238000011091 antibody purification Methods 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 241000282330 Procyon lotor Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 208000027687 belching Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003317 industrial substance Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical compound [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940045872 sodium percarbonate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241001416153 Bos grunniens Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010059158 Infrequent bowel movements Diseases 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 241001508691 Martes zibellina Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241001482564 Nyctereutes procyonoides Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001502395 Ovibos moschatus Species 0.000 description 1
- 241000609816 Pantholops hodgsonii Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/358—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0275—Containing agglomerated particulates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/02—Silicon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Definitions
- the present invention relates to an oxidative stress inhibitor and an antioxidant.
- the hydroxyl radical generated in the body disappears by reacting with some substances.
- an antioxidant substance in the living body such as polyphenol, vitamin C, ⁇ -tocopherol, or glutathione is generally presumed.
- these substances eliminate not only hydroxyl radicals but also active oxygen having a function in the body such as hydrogen peroxide, there is a possibility of causing adverse effects (side effects) such as a decrease in immunity.
- side effects such as a decrease in immunity.
- hydrogen can also extinguish hydroxyl radicals.
- hydrogen reacts only with hydroxyl radicals in active oxygen, it does not have the above-mentioned adverse effects (side effects). Therefore, a hydrogen water generator containing hydrogen that eliminates hydroxyl radicals in the body has been proposed (for example, Patent Document 1).
- Patent Document 3 a solid preparation which contains silicon fine particles as a main component and has a high hydrogen generating ability and can be used orally is disclosed. Further, the silicon fine particles and the silicon suboxide (SiO X , x in the formula are 1/2, 1, and 3/2) and / or the silicon suboxide covering at least a part of the surface of the silicon fine particles.
- Patent Document 4 A composite material containing a mixed composition of silicon dioxide and silicon dioxide is disclosed (Patent Document 4).
- the oxidative stress in the human body caused by the above-mentioned hydroxyl radical is considered to be one of the causes of human aging. Therefore, prevention or improvement of human aging can greatly contribute to the improvement of the national medical economy represented by social security expenses such as medical expenses as well as individuals by prolonging the healthy life expectancy of humans.
- the present invention can greatly contribute to solving at least one of the above-mentioned technical problems and making the hydrogen generation ability (generation ability) of silicon particles or silicon fine particles stronger.
- a large amount of hydrogen can be rapidly generated in the human body, a space containing various waters, or a water-containing liquid depending on the situation, or can greatly contribute to more accurate extraction of a large amount of hydrogen.
- the present inventor has conducted extensive studies and analysis in order to improve the constitution of humans, improve health, and treat or prevent various diseases by utilizing substances with high hydrogen-generating ability.
- generation of hydrogen it is required to design a substance in consideration of the total amount of hydrogen generated (total amount of production) and the amount of hydrogen generated per unit time (that is, the rate of hydrogen generation), especially in the initial stage. Therefore, in order to enhance the hydrogen generation ability, the present inventor has made "silicon fine particles" in which particles having an average crystallite diameter of 1 nm or more and less than 1 ⁇ m are the main particles.
- sicon fine particles in which particles having an average crystallite diameter of 1 nm or more and less than 1 ⁇ m are the main particles.
- silicon particles or silicon fine particles (hereinafter, also collectively referred to as "silicon particles") by a method different from the production methods adopted so far.
- the different production method includes a classification step for obtaining silicon particles having a relatively constant size and a particle size after a step of crushing the silicon particles.
- the present inventor conducted a study including the influence of other elements while using silicon (Si) as one of the elements in order to enhance the hydrogen generating ability. By adopting these manufacturing methods, we proceeded with research and analysis to find substances that can exhibit high hydrogen generation ability.
- silicon particles having a hydrogen-generating ability can play a role as an oxidative stress inhibitor. More preferably, the silicon particles include silicon particles having a crystallite diameter of 1 nm or more and 500 ⁇ m or less. Then, in particular, it was found that by adopting silicon particles having the following characteristics (1) and / or (2), the hydrogen generating ability is further strongly generated as compared with the conventional case. (1) The ratio of the silicon fine particles having a crystallite diameter of less than 1 ⁇ m and the aggregates of the silicon fine particles to all the silicon particles, the silicon fine particles and their aggregates is 5% by mass or less. matter.
- Physiologically acceptable, supported, attached, or adsorbed on the surface of the silicon particles or at least a part of the surface of the silicon fine particles, or chemically bonded to the surface Possible or medically acceptable metals (hereinafter collectively referred to as “physiologically acceptable metals”), more specifically iron (Fe) or iron (Fe) -containing substances (hereinafter collectively referred to as “generic”). And “iron (Fe)”), to be provided.
- the total amount of hydrogen generated (total amount of hydrogen produced) of the silicon particles and / or the amount of hydrogen generated per unit time in the initial stage can be reduced.
- the present inventor has found that it is significantly superior to those of conventional silicon fine particles.
- the silicon particles of the above (1) are silicon particles of less than 1 ⁇ m with respect to the entire silicon particles (and the aggregates) and the coagulation. Since the abundance ratio of the aggregate is low, the hydrogen generating ability can be maintained high, and more stable hydrogen generating ability can be exhibited by keeping the crystallite diameter within a certain range. In addition, in the case of oral ingestion, deterioration of human texture can be suppressed. In addition, it is possible to prevent the silicon particles from being directly absorbed and invading the blood vessels with high accuracy.
- the film thickness of the mixed composition of the silicon suboxide and silicon dioxide is the thickness of the conventional silicon fine particles.
- An interesting finding was obtained that it was larger than the film thickness.
- the silicon particles of the above (2) are the silicon particles of the above (1) containing relatively large particles, the hydrogen generating ability is strongly generated.
- the silicon particles when the silicon particles have a film of silicon suboxide covering at least a part of the surface of the silicon fine particles or the silicon particles, the "surface" of the silicon particles is the silicon suboxide and silicon dioxide.
- the silicon particles include a film of the mixed composition with, or when the silicon particles include a natural oxide film, the surface of the film of the silicon suboxide and the film of the mixed composition, respectively. It means the surface or the surface of the natural oxide film.
- the present invention was created from each of the above viewpoints.
- the "silicon fine particles” in the present application are mainly particles having an average crystallite diameter of 1 nm or more and less than 1 ⁇ m.
- the "silicon fine particles” in the present application mainly consist of silicon nanoparticles having an average crystallite diameter of nano-level, specifically, a crystallite diameter of 1 nm or more and 500 nm or less.
- the "silicon particles” in the present application are mainly particles having an average crystallite diameter of more than 500 nm (more narrowly, 1 ⁇ m or more) and 500 ⁇ m or less.
- the "silicon fine particles” are not limited to those in which each silicon fine particles are dispersed, but also have a size of ⁇ m order (generally 0.1 ⁇ m or more) in which a plurality of silicon fine particles are aggregated. Includes those in the state of forming aggregates. Since each of the above-mentioned numerical ranges of "silicon fine particles” is only an example, the numerical range is not limited. Further, the crystallite diameter is appropriately selected according to the use, usage, required function, etc. of the "silicon fine particles” or "silicon particles”.
- the "water-containing liquid” in the present application is water or an aqueous solution, and includes, for example, a human digestive tract liquid.
- the "digestive tract fluid” refers to the fluid in the small intestine and the fluid in the large intestine.
- the example of the "water-containing liquid” is not limited to the above-mentioned example.
- the material of the "pH adjuster” in the present application is particularly limited as long as it is a drug (hereinafter, "alkaline agent") capable of adjusting the pH value to an alkaline range of more than 7 (typically, more than 7.4). Not done. It also includes its use on human skin.
- a drug quadsi-drug
- a quasi-drug or an alkaline agent recognized as a food additive
- alkaline agents sodium hydrogen carbonate, sodium carbonate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium hydrogen carbonate, potassium carbonate, and other pH adjusters for pharmaceuticals, non-pharmaceutical products, or foods. Can be adopted.
- sodium hydrogen carbonate which is the most general-purpose product, is widely used as a pharmaceutical product, a quasi-drug, or a food additive, and has a plurality of pH value adjusting functions required by the present invention and excellent safety and versatility. This is to combine the advantages. It is a preferable aspect that any pH adjusting agent has a form that is not decomposed by an acid. In particular, when the oxidative stress inhibitor of the present application is orally ingested, it is preferable that the oxidative stress inhibitor is not decomposed by gastric acid or is hardly decomposed.
- One oxidative stress inhibitor of the present invention includes silicon particles and silicon fine particles having a hydrogen generating ability.
- oxidative stress in the human body caused by hydroxyl radical can be suppressed.
- at least one of the following effects (a) to (c) can be exhibited.
- (c) When ingested orally it is possible to prevent silicon particles from being directly absorbed and invading blood vessels.
- the above-mentioned silicon particles are all the silicon particles of the silicon fine particles having a crystallite diameter of less than 1 ⁇ m and an aggregate of the silicon fine particles, the silicon fine particles, and the silicon fine particles thereof.
- the ratio to the agglomerates is 5% by mass or less (more preferably 3% by mass or less, further preferably 1% by mass or less, still more preferably 0.5% by mass or less, still more preferably 0.2% by mass or less. ),
- the oxidative stress inhibitor can exert at least one of the above-mentioned effects (a) to (c) with higher accuracy.
- the above-mentioned oxidative stress inhibitor is further supported, attached to, or adsorbed on at least a part of the surface of the above-mentioned silicon particles or the above-mentioned surface of the above-mentioned silicon fine particles.
- the provision of iron (Fe) which is formed or chemically bonded to the surface can more accurately achieve at least one of the above-mentioned effects (a) to (c).
- the amount of hydrogen generated increases due to the catalytic action of the metal element by supporting, adhering, or adsorbing the metal element (hereinafter, collectively referred to as "support").
- support the metal element
- the film thickness of the silicon suboxide covering at least a part of the surface of the silicon fine particles or the silicon particles and / or the film thickness of the mixed composition of the silicon suboxide and silicon dioxide is conventionally set. It is possible to make the film thickness of the silicon fine particles of No. 1 larger than that of the above.
- one oxidative stress inhibitor of the present invention contributes to the maintenance or promotion of human health or the prevention or improvement of human aging.
- the following (1) Supplements for prevention or improvement of diseases or symptoms (including symptoms) of (5), foods (including food additives and health foods), or diseases or symptoms (including symptoms) of (1) to (5) below ) Can serve as a prophylactic or therapeutic preparation.
- skin disease includes at least one selected from the group of eczema, inflammatory skin disease, skin barrier dysfunction allergic dermatitis, contact dermatitis, and atopic dermatitis.
- One oxidative stress inhibitor of the present invention is an oxidative stress inhibitor excellent in the total amount of hydrogen generated (total amount produced) and / or the amount of hydrogen generated per unit time in the initial stage.
- FIG. 1 It is a schematic diagram (a) of the oxidative stress inhibitor of the first embodiment, and the schematic diagram (b) of the oxidative stress inhibitor of the modification (1) of the first embodiment. It is a graph which shows the time change of hydrogen generated by the reaction between the oxidative stress inhibitor of Example 1 and Example 2, and the comparative example and a water-containing liquid.
- 3 is a cross-sectional TEM image showing each silicon oxide film thickness of the oxidative stress inhibitor (a) and Comparative Example (b) of Example 1. After taking (a) a photograph showing the condition of the palm before ingesting the oxidative stress inhibitor and (b) 1 g of the oxidative stress inhibitor daily for 5 days, the tester confirming the effect of the oxidative stress inhibitor. In addition, it is a photograph showing the situation of the palm.
- FIG. 1A is a schematic view of the oxidative stress inhibitor 100 of the present embodiment.
- the oxidative stress inhibitor 100 of the present embodiment includes silicon particles or silicon fine particles (hereinafter collectively referred to as “silicon particles”) 10 having a hydrogen generating ability. ..
- all of the silicon fine particles containing the silicon particles 10 and the silicon fine particles 10 and having a crystallite diameter of less than 1 ⁇ m and an aggregate of the silicon fine particles is 5% by mass or less (more preferably 3% by mass or less, still more preferably 1% by mass or less, still more preferably 0.5% by mass). Hereinafter, more preferably 0.2% by mass or less).
- ⁇ Crushing process> for example, commercially available high-purity silicon particle powder (particle size 300 ⁇ m or less, purity 99.999%, i-type silicon) is used as a part of the raw material of the oxidative stress inhibitor 100.
- silicon particle powder having a purity higher or lower than the above-mentioned purity can be adopted.
- a crushing step is performed on the above-mentioned high-purity silicon particle powder by a crushing process using a cutter by a jet mill method.
- an additional pulverization step (second pulverization step) using 0.5 mm ⁇ zirconia beads in ethanol is performed in the bead mill method. It is also an embodiment in which it is possible to obtain silicon fine particles (silicon nanoparticles) 10 having a typical crystallite diameter) of less than 500 nm.
- a roller mill method instead of the first pulverization step, a roller mill method, a high-speed rotary pulverization method, or a container-driven mill method is used to obtain silicon particles 10 having a crystallite diameter of 1 ⁇ m or more and 60 ⁇ m or less, or a typical crystallite diameter.
- a classification step is performed between the crushing step (first crushing step or the second crushing step) of the present embodiment and the metal element supporting step described later.
- the ratio of the aggregates of the silicon fine particles 10 and the silicon fine particles 10 having a crystallite diameter of less than 1 ⁇ m to all the silicon particles 10, the silicon fine particles 10 and the aggregates thereof is 5% by mass or less. (More preferably 3% by mass or less, further preferably 1% by mass or less, further preferably 0.5% by mass or less, still more preferably 0.2% by mass or less) using the air flow method.
- aggregates of silicon fine particles 10 and silicon fine particles 10 having a crystallite diameter of less than 1 ⁇ m are substantially removed.
- crystallite diameter used for the silicon particles 10
- crystal particle size is used as a term for the overall diameter of the aggregates of the silicon particles 10.
- the oxidative stress inhibitor 100 having a hydrogen generating ability of the present embodiment includes all of the silicon particles 10 and the silicon fine particles 10 and the aggregates of the silicon fine particles 10 and the silicon fine particles 10 having a crystallite diameter of less than 1 ⁇ m.
- the ratio of the silicon particles 10, the silicon fine particles 10 and their aggregates to the aggregates is 5% by mass or less (more preferably 3% by mass or less, still more preferably 1% by mass or less, still more preferably 0.5% by mass). % Or less, more preferably 0.2% by mass or less), which has an effect that the safety can be enhanced by preventing the oxidative stress inhibitor 100 from passing through the cell membrane of the intestinal tract and between cells. Can be played.
- the upper limit of the crystallite diameter of the silicon particles 10 and the aggregates of the silicon particles 10 is not limited.
- Classification to be% or less (more preferably 3% by mass or less, further preferably 1% by mass or less, further preferably 0.5% by mass or less, still more preferably 0.2% by mass or less).
- the process can be adopted.
- the hydrogen generating ability can be maintained high and the crystallite diameter is constant.
- the crystallite diameter is constant.
- deterioration of human texture can be suppressed.
- the ratio of the silicon fine particles having a crystallite diameter of less than 1 ⁇ m and the aggregates of the silicon fine particles to all the silicon particles, the silicon fine particles and their aggregates is 5% by mass.
- an aggregate of silicon particles 10 and silicon particles 10 having a crystallite diameter of 1 ⁇ m or more and 60 ⁇ m or less (more preferably 1 ⁇ m or more and less than 45 ⁇ m) can be obtained.
- the oxidative stress inhibitor 100 of the present embodiment is excellent from the viewpoint of suppressing the deterioration of the texture of the silicon particles or reducing the possibility of silicon particles entering the blood vessels.
- an aqueous sodium hydrogen carbonate solution pH 8.3
- the amount of hydrogen generated was 295 mL / g.
- the amount of hydrogen generated by the oxidative stress inhibitor 100 under the same conditions as described above was 430 mL / g, it can be seen that the hydrogen generating ability of the oxidative stress inhibitor 100 of the present embodiment is remarkably excellent.
- the oxidative stress inhibitor 100 having the silicon particles 10 and the agglomerates of the silicon particles 10 can be obtained.
- FIG. 1B is a schematic view of the oxidative stress inhibitor 200 of this modified example.
- the oxidative stress inhibitor 200 of this modified example includes silicon particles or silicon fine particles (hereinafter collectively referred to as “silicon particles”) 10 having a hydrogen generating ability and silicon. It comprises a physiologically acceptable metal element 20 that is carried, attached, or adsorbed to, or chemically bonded to, the surface of the particles 10 or at least a portion of the surface of the silicon fine particles 10.
- the metal element 20 is iron (Fe).
- the state in which the metal element 20 is physically adsorbed on the silicon particles 10 is an example in which the surface of the silicon particles 10 or the surface of the silicon fine particles 10 supports the metal element 20.
- a compound for example, VDD
- VDD a compound is formed in a state where a part of the metal element 20 and the surface of the silicon particles 10 are chemically adsorbed, and in a region where the metal element 20 and the surface of the silicon particles 10 are in contact with each other.
- the state is an example in which the surface of the silicon particles 10 and the metal element 20 are chemically bonded.
- the amount of the metal element 20 supported on or chemically bonded to the surface of the silicon particles 10 or the surface of the silicon fine particles 10 is not particularly limited.
- a typical amount of the metal element 20 is 0.1 ppmw or more and 1000 ppmw or less in terms of mass ratio.
- the amount of the metal element 20 is preferably the metal element 20 in terms of mass ratio. It is 0.5 ppmw or more (more preferably 1 ppmw or more, more preferably 1.5 ppmw or more, still more preferably 2 ppmw or more), and the upper limit of the numerical range is preferably 500 ppmw or less (more preferable). 300 ppmw or more, more preferably 100 ppmw or more, still more preferably 75 ppmw or less, still more preferably 50 ppmw or less).
- a metal element is further formed on the surface of the silicon particles 10 or the surface of the silicon fine particles 10.
- a step of supporting, adhering, or adsorbing 20 or a chemical bonding step of chemically bonding the metal element 20 and the surface of the silicon particles 10 (hereinafter, collectively referred to as “supporting step”) is performed.
- a solution of a metal element 20 for example, iron (Fe)
- a metal element 20 for example, iron (Fe)
- aqueous chloride solution for example, an aqueous chloride solution
- Spraying treatment using the device is performed.
- a spraying step of spraying a 10 mM FeCl 2 aqueous solution onto the silicon particles 10 is performed.
- the solution of the metal element 20 is a part of the raw material of the oxidative stress inhibitor 200.
- the oxidative stress inhibitor 200 of this modified example can be produced.
- another step of bringing the silicon particles 10 into contact with the solution of the metal element 20 may be adopted in place of or in combination with the spraying step described above.
- a step of manually or automatically immersing the silicon particles 10 in the solution of the metal element 20 by using a storage portion for accommodating the solution of the metal element 20 can be adopted. ..
- a crushing process using a SUS cutter is performed, and the composition of the cutter is utilized in the crushing process, for example, iron.
- a step of supporting, adhering, or adsorbing (Fe) on the surface of the silicon particles 10 or the surface of the silicon fine particles 10 can be adopted.
- the above-mentioned crushing step can also play the role of the supporting step of the present embodiment.
- the present inventor analyzes the total amount of hydrogen (H 2 ) generated (total amount of production) and the rate of hydrogen generation (production rate) by performing a contact step of bringing the water-containing solution into contact with the oxidative stress inhibitor 200. Therefore, it is an aqueous solution containing sodium hydrogen carbonate as a solute using the oxidative stress inhibitor 200 as a pH adjuster, and is immersed in a water-containing solution (pH value is 8.2) at a temperature (37 ° C.) equivalent to human body temperature. ..
- Example 1 is an oxidative stress inhibitor 200 in which the surface of the silicon particles 10 or a part of the surface of the silicon fine particles 10 carries the metal element 20 or the surface and the metal element 20 are chemically bonded.
- the metal element 20 of Example 1 is iron (Fe).
- the metal element 20 with respect to the silicon particles 10 is about 10 ppmw.
- Example 2 In Example 2, similarly to Example 1, the surface of the silicon particles 10 or a part of the surface of the silicon fine particles 10 carries the metal element 20 or the surface and the metal element 20 are chemically bonded.
- the metal element 20 of Example 2 is iron (Fe).
- the metal element 20 with respect to the silicon particles 10 is about 5 ppmw.
- the metal with respect to the silicon particles in the comparative example is less than 0.1 ppmw, or more narrowly, below the detection limit when an inductively coupled plasma mass spectrometer is used.
- FIG. 2 is a graph showing the time change of hydrogen generated by the reaction between the oxidative stress inhibitor 200 of Examples 1 and 2 and the silicon particles of Comparative Example and the water-containing liquid.
- Example 1 As shown in FIG. 2, among the oxidative stress inhibitor 200, in Example 1, not only the amount of hydrogen generated (591 mL (milliliter) / g (gram)) was large, but also immediately after hydrogen was generated ( In particular, it was revealed that the amount of hydrogen (mL / g) per unit mass (within 2 to 3 hours after hydrogen generation) was very large. Specifically, the amount of hydrogen generated up to 3 hours after the generation of hydrogen was a very high value of about 385 mL / g. It is worth noting that, as in Example 1, high hydrogen generating ability can be exhibited for a long time of 40 hours or more (at least 48 hours in one example) from the start of hydrogen generation.
- Example 2 In addition, among the oxidative stress inhibitor 200, in Example 2, not only the total amount generated (368 mL / g) is relatively large, but also immediately after hydrogen is generated (particularly within 2 to 3 hours after hydrogen generation). It was revealed that the amount of hydrogen (mL / g) per unit mass was relatively large. Specifically, the amount of hydrogen generated up to 3 hours after the generation of hydrogen was a relatively high value of about 170 mL / g. It is worth noting that, as in Example 2, a high hydrogen generating ability can be exhibited for a long time of 40 hours or more (at least 48 hours in one example) from the start of hydrogen generation.
- the inventor of the present application adopts iron (Fe) as the metal element 20 and sets the mass ratio of the metal element 20 to the silicon particles 10 to be about the same as in Example 1.
- Fe iron
- the amount of hydrogen per unit mass (mL / g) was examined for the cases of 0.5 ppmw, about 1.5 ppmw, and about 2.0 ppmw, in each case, immediately after hydrogen was generated (particularly, hydrogen generation).
- the amount of hydrogen (mL / g) (so to speak, hydrogen generation rate) per unit mass (within 2 to 3 hours after that) showed a higher value than that of the comparative example.
- FIG. 3 is a cross-sectional TEM image showing the film thickness of each silicon oxide of the oxidative stress inhibitor (a) and Comparative Example (b) of Example 1 described above.
- the film thickness (about 113.9 nm) of the silicon oxide of the oxidative stress inhibitor 200 of Example 1 is that of the silicon oxide of the comparative example. It was confirmed that the thickness was 17 times or more the film thickness (about 6.4 nm). Although the detailed mechanism is not clear at this time, it is considered that a part of the metal element 20 on the surface of the silicon particles 10 exerts a catalytic effect. As a result, the hydrogen generation reaction is promoted as compared with the case where the metal element 20 is absent, and as a result, the film thickness of the silicon suboxide and / or the film thickness of the mixed composition of the silicon suboxide and silicon dioxide. It is considered that a situation can be formed in which it is easy to increase (in other words, it is easy to cause a hydrogen generation reaction).
- the film thickness of the silicon suboxide covering at least a part of the surface of the silicon particles 10 and / or the film thickness of the mixed composition of the silicon suboxide and silicon dioxide is larger than the film thickness of the conventional silicon fine particles. Become. The fact that the film thickness is large makes the reaction in which silicon and water (or water in a water-containing liquid) come into contact with each other to form silicon oxide and hydrogen, as compared with conventional silicon fine particles. It shows that it can occur high.
- the hydrogen generating ability of the oxidative stress inhibitor 200 is more strongly generated.
- a large amount of hydrogen can be generated quickly and for a long time depending on the situation in the human body or in a space containing various waters or in a water-containing liquid, or can greatly contribute to drawing out a large amount of hydrogen with higher accuracy.
- the silicon particles containing the silicon nanoparticles can be made hydrophilic when viewed macroscopically.
- the silicon particles are immersed in a hydrogen peroxide solution (for example, about 10 ° C. to about 80 ° C., about 20 ° C. to about 50 ° C. from the viewpoint of realizing lower cost) contained in a known container. Thereby, the reforming step can be performed.
- the same modification can be realized by immersing the silicon particles in ozone water and / or sodium percarbonate instead of the hydrogen peroxide solution.
- similar modification can be achieved by contacting the silicon particles with at least one selected from the group of hydrogen peroxide solution, ozone water, and sodium percarbonate.
- oxidative stress inhibitors 100 and 200 having stable silicon suboxides and pH adjusters such as sodium hydrogen carbonate are separately not dissolved under acidic conditions, but are dissolved under basic conditions, such as nanocapsules, microcapsules, and ordinary ones. Capsule or coating is a preferred embodiment.
- oxidative stress suppressants 100 and 200 of the above-mentioned first embodiment or modifications (1) to (3) of the first embodiment are utilized as, for example, a pharmaceutical product (medicinal product) or a quasi-drug. be able to.
- the application examples are not limited to tablets.
- Oxidative stress inhibitors 100 and 200 can generate more hydrogen when they are in the form of powder with a large surface area rather than in the form of lumps, but they are easier to take orally or through the anus than in tablets or capsules. become.
- the surface area of the oxidative stress inhibitors 100 and 200 exposed to the gastric juice and / or the contents of the stomach is reduced, and in the small intestine and / or the large intestine where the hydrogen generation reaction is desired to be promoted.
- the surface area exposed to the water-containing liquid can be increased.
- the oxidative stress inhibitors 100 and 200 may be prepared as granules.
- Granule preparations are powdery at an earlier stage after ingestion or anal ingestion compared to tablets and capsules.
- gastric juice has a low pH value (about 1.5), so even if it reaches the stomach and immediately becomes powdery, it hardly generates hydrogen, and in the presence of water after passing through the stomach. To generate hydrogen.
- the oxidative stress suppressants 100 and 200 may be powders.
- the powder is easy to handle when the constituents of foods including health foods, for example, oxidative stress inhibitors 100 and 200 are used as food additives.
- silicon particles 10 having a crystallite diameter of 1 nm or more and 10 ⁇ m or less, or 1 nm or more and 500 nm or less (more narrowly, 1 nm or more and 100 nm or less) are mixed and used as oxidative stress inhibitors 100 and 200.
- the silicon particles 10 are preferably contained in an amount of 1% by mass or more. Although there is no upper limit to the content of the silicon particles 10, it is preferably 40% by mass or less in consideration of the taste.
- An example of a coating layer applicable to a tablet is a known poorly soluble gastrointestinal enteric material, which is a coating agent covering the outermost layer of a tablet.
- An example of a coating layer applicable to a capsule is a capsule itself produced from a known poorly soluble enteric material in the stomach, which contains oxidative stress inhibitors 100 and 200.
- examples of the preparations suitable as utilization examples of the oxidative stress suppressors 100 and 200 are tablets or powdery oxidative stress suppressors, which are lumpy preparations that are easily taken orally in a sufficient amount or easily taken through the anus. It is a capsule agent in which agents 100 and 200 (which may include those in an aggregated state) are encapsulated.
- a disintegrant may be further contained.
- the disintegrant a known material can be adopted.
- a more preferred example of a disintegrant is an organic acid, the most preferred example is citric acid.
- the organic acid can also function as a binder that agglomerates the silicon particles 10.
- the oxidative stress inhibitors 100 and 200 can also be used, for example, as a granular, flake-like, and / or rag-like food topping material (typically, "sprinkle") for each food material.
- the oxidative stress inhibitores 100 and 200 of the above-mentioned first embodiment or modifications (1) to (4) of the first embodiment are, for example, "mediums” that are brought into contact with the oxidative stress inhibitor 100,200.
- the medium of this modification is not particularly limited to materials or products. Any physiologically acceptable medium can produce the effects of this variant. Therefore, the one provided with the oxidative stress inhibitor 100, 200 and the medium in contact with the oxidative stress inhibitor 100, 200 can exhibit a function as a hydrogen supply material.
- a human part in a living scene, may be water (or a water-containing liquid) or a medium containing the water (or a water-containing liquid) (hereinafter, also collectively referred to as “medium”).
- suitable vehicles are at least one selected from the liquid, gel, cream, paste, emulsion, and mousse groups.
- An example of another suitable medium is bath water (preferably alkaline bath water). Therefore, in one example of this modification, the production of the bath water is the method for producing the medium.
- tap water is typically stored as bathing water in a general bathtub (including a public bathtub, a public bathtub, and an indoor or outdoor bathtub installed by an inn).
- a general bathtub including a public bathtub, a public bathtub, and an indoor or outdoor bathtub installed by an inn.
- hydrogen (H) is formed by arranging or putting the above-mentioned oxidative stress inhibitor in the bathtub and performing a contact step of bringing the oxidative stress inhibitors 100 and 200 into contact with the bath water as a medium. 2 ) is generated. Therefore, the oxidative stress suppressants 100 and 200 of this modification can be adopted as so-called bath salts.
- hydrogen (H 2 ) generated by the above-mentioned contact step can be brought into contact with the human skin and / or mucous membrane to be bathed via bath water as a physiologically acceptable medium.
- FIG. 4 shows a photograph showing the state of the palm of the tester confirming the effect of the oxidative stress inhibitor (a) before ingesting the oxidative stress inhibitor, and (b) the palm 5 days after ingesting the oxidative stress inhibitor. It is a photograph showing the situation of.
- a tester male, 30s who participated by his / her own will, who had eczema and atopic dermatitis on the palm, participated every day.
- 1 g / day of oxidative stress inhibitor 100 was orally ingested.
- both the symptoms of eczema and atopic dermatitis had a clear improving effect. It was observed. According to the tester, itching of the hands was also improved.
- Example 4 [Effect of oxidative stress suppressant on constipation or diarrhea]
- testers who participated in this example on their own initiative with constipation or diarrhea with infrequent bowel movements (constipation: women in their 20s, women in their 40s, women in their 60s).
- 1 g / day of the oxidative stress inhibitor 100 was orally ingested every day.
- the examiner confirmed whether or not the bowel movement was improved and / or the number of healthy bowel movements, and found that all the symptoms were improved.
- the improvement effect on constipation and diarrhea was obtained by ingesting the oxidative stress inhibitor.
- the oxidative stress inhibitor can play a role as an agent for improving the human intestinal environment or a human intestinal regulator.
- Example 5 [Effect of oxidative stress suppressant on hangover syndrome]
- testers male in their 30s, male in their 40s, male in their 50s who participated in this example on their own initiative for hangover syndrome (a series of physiological symptoms called "hangover").
- a male in his 60s took 1 g / day of an oxidative stress inhibitor 100 orally every day. Then, when it was confirmed whether or not the tester's symptoms of hangover were improved after 2 days or more had passed from the start of ingestion of the oxidative stress inhibitor, an improvement effect was observed.
- the "hangover syndrome” includes each phenomenon of nausea, vomiting, headache, drowsiness, and decreased athletic ability. It is also well known that acetaldehyde produced in the body during or after alcohol intake is the cause of hangover syndrome.
- the oxidative stress suppressants 100 and 200 of the above-mentioned first embodiment or each modification of the first embodiment can also be used as supplements for humans and food additives. Therefore, the food containing the oxidative stress suppressants 100 and 200 of each of the above-mentioned first embodiment or each modification of the first embodiment is a preferable embodiment that can be adopted.
- the oxidative stress suppressants 100 and 200 of the above-mentioned first embodiment or each modification of the first embodiment have a diameter of ⁇ m level (for example, several tens of ⁇ m or more) by agglutinating in a natural state. It may constitute an agglomerate of size.
- a lumpy solid preparation having a size that can be pinched by human fingers is formed. can do.
- the first contact step in which the pH value is less than 7. It can be brought into contact with a water-containing liquid, and in a subsequent contact step (second contact step), it can be brought into contact with a second water-containing liquid having a pH value of 7 or more, and hydrogen can be generated in the second contact step.
- the oxidative stress inhibitors 100 and 200 of each of the above-described embodiments are markedly hydrogen when they come into contact with a water-containing liquid having a pH value of 7 or more (more preferably more than 7 and more preferably 8.2 or more). May have developmental potential.
- the temperature conditions of the second water-containing liquid for hydrogen generation described above are not limited. Although it may depend on the pH of the second water-containing liquid, if the temperature of the second water-containing liquid is 80 ° C. or lower, the accuracy is high and hydrogen generation can be promoted.
- the upper limit of the temperature of the second water-containing liquid is not originally limited. For example, when the oxidative stress suppressants 100 and 200 of each of the above-described embodiments and modifications thereof are used as industrial chemicals, the temperature may exceed 50 ° C. However, the higher the temperature, the higher the heat resistance of the equipment (including the container) is required, and there are problems that care must be taken in handling. Therefore, even when used as an industrial chemical, it is preferably used at 100 ° C. or lower.
- Inhibitors 100 and 200 can be supplements for the prevention or improvement of all diseases or symptoms (including symptoms) of (1) to (5) below, foods (including food additives and health foods), or the following (including food additives and health foods). It can serve as a prophylactic or therapeutic preparation for the diseases or symptoms (including symptoms) of 1) to (5).
- the oxidative stress suppressants 100 and 200 of each of the above-described embodiments and modifications thereof can play a role as an antioxidant or a preventive (or ameliorating) agent for aging. Therefore, in the present specification, the oxidative stress inhibitor 100, 200 can be read as an antioxidant 100, 200, a hydroxyl radical inhibitor 100, 200, or an aging preventive (or ameliorating) agent 100, 200.
- the other technical ideas derived from the first embodiment or the modifications of the first embodiment described above include at least the following (A) to (F) in addition to the technical ideas already described. ..
- Antioxidant (C) In the above-mentioned (A) or (B), the surface of the silicon particles.
- D Crystalline diameter in (D) described above.
- a hydroxyl radical inhibitor in which the ratio of the silicon fine particles having a size of less than 1 ⁇ m and the aggregates of the silicon fine particles to all the silicon particles, the silicon fine particles and the aggregates thereof is 5% by mass or less ( F)
- the surface of the silicon particles or at least a part of the surface of the silicon fine particles is supported, adhered, or adsorbed, or with the surface.
- a hydroxyl radical inhibitor comprising a chemically bound, physiologically acceptable or medically acceptable metal element (iron (Fe)).
- an oxidative stress inhibitor, an antioxidant, and / or a hydroxyl radical inhibitor containing the silicon particles having a hydrogen generating ability and the silicon fine particles is used. It is used in at least one step selected from the following group of steps (I) to (IV).
- II Separation step of the antibody-producing cell and / or the plasma cell
- IV Monoclonal antibody production step of producing a monoclonal antibody
- the antioxidant of the present embodiment can be used. Since the antioxidant can eliminate some or almost all of the hydroxyl radicals that may occur in the preparation step, it can enhance the efficiency of inducing or inducing the antibody response in the conditioning step.
- non-human animals examples include rats, mice, monkeys, sheep, goats, rabbits, camels, llamas, alpaca, vicuna, guanaco, yak, cow, musk ox, tibetan antelope, raccoon dog, mink, sable, and raccoon.
- plant is at least one plant selected from the group of rice, corn, and various wheats (barley, wheat, rye).
- the antioxidant of the present embodiment can be used. Since the antibody-producing cells and / or the plasma cells can generate hydroxyl radicals, oxidative stress on the cells can result in damage, death, dysfunction, and / or dysfunction of the cells. .. Therefore, since the antioxidant can eliminate a part or almost all of the hydroxyl radicals that may be generated in the separation step, the recovery efficiency of the antibody-producing cells and / or stromal cells in the separation step can be improved. ..
- the hybridoma cells are produced by fusing the antibody-producing cells and / or plasma cells described in the separation step of (II) above with myeloma cells.
- the antioxidant of the present embodiment can be used.
- the antibody-producing cells and / or the plasma cells can generate hydroxyl radicals, so that the cells are damaged or killed by applying oxidative stress to the cells. Deterioration and / or dysfunction can occur.
- the antioxidant can eliminate a part or almost all of the hydroxyl radicals that may be generated in the hybridoma cell production step, the production of the antibody-producing cells and / or exoplasmic cells in the hybridoma cell production step. It can improve efficiency.
- the monoclonal antibody production step (IV) above for example, when a monoclonal antibody is isolated from a hybridoma cell that produces an antibody that specifically exhibits an antigen (including a peptide and a recombinant protein).
- the antioxidant of this embodiment can be used. Since the antioxidant can eliminate some or almost all of the hydroxyl radicals that may be generated in the monoclonal antibody production step, the functional improvement of the monoclonal antibody obtained in the monoclonal antibody production step and / or the monoclonal is performed. It can contribute to the improvement of antibody yield.
- the antioxidant of the present embodiment can also be utilized in the monoclonal antibody purification step of purifying the monoclonal antibody. Therefore, since a part or almost all of hydroxyl radicals that may be generated in the monoclonal antibody purification step can be eliminated, the purification efficiency in the monoclonal antibody purification step can be improved.
- the antioxidant for example, the granular or massive antioxidant
- the antioxidant is brought into contact with the solution directly, so to speak, without the intervention of a medium, a covering, a support, a holding body, or the like. Can be made to.
- a bag body composed of a mesh filter through which only the solution can pass and containing the antioxidant is brought into contact with the solution so that the antioxidant does not diffuse into the solution.
- Can be placed eg, placed in a container containing the solution.
- the antioxidant in this example is preferably one embodiment in which the particle size distribution of the antioxidant is adjusted by using the classification step in the first embodiment.
- a non-woven fabric containing the antioxidant in a part of the surface and / or the inside instead of the bag body described above (for example, a part or all of the non-woven fabric shown in Japanese Design Registration No. 1561310). ) Can be adopted.
- the bag body or the non-woven fabric is used in a clean state after being sterilized.
- the antioxidant for example, the granular or massive antioxidant
- the antioxidant can also be used in a known bioreactor.
- oxidative stress inhibitor used in vitro fertilization / embryo transplantation methods. It can also be utilized when culturing cells in the above, or at least one cell selected from the group of ES cells, iPS cells (induced pluripotent stem cells) and somatic stem cells.
- the cells when culturing each of the above-mentioned cells, the cells can generate hydroxyl radicals, and therefore, oxidative stress applied to the cells causes damage, death, functional deterioration, and / or function of the cells. Failure can occur. Therefore, the antioxidant can eliminate some or almost all of the hydroxyl radicals that can be generated from the cell, which can improve the production efficiency or yield of the cell.
- a liquid or solution (typically, an aqueous solution) (hereinafter, collectively referred to as “solution”) is used in the above-mentioned culturing process of each cell.
- solution typically, an aqueous solution
- the following method can be adopted.
- the antioxidant for example, the granular or massive antioxidant
- the solution for example, an in vitro growth culture solution
- a bag body composed of a mesh filter through which only the solution can pass and containing the antioxidant is brought into contact with the solution so that the antioxidant does not diffuse into the solution.
- Can be placed eg, placed in a container containing the solution.
- the antioxidant in this example is preferably one embodiment in which the particle size distribution of the antioxidant is adjusted by using the classification step in the first embodiment.
- a non-woven fabric containing the antioxidant in a part of the surface and / or the inside instead of the bag body described above (for example, a part or all of the non-woven fabric shown in Japanese Design Registration No. 1561310). ) Can be adopted.
- the bag body or the non-woven fabric is used in a clean state after being sterilized.
- the oxidative stress inhibitor of the present invention can be widely used in various industries including the pharmaceutical (including quasi-drugs) and medical industries that utilize hydrogen, and the food industry.
- Silicon particles Silicon fine particles 20
- Metal elements 100, 200 Oxidative stress inhibitors, antioxidants, hydroxyl radical inhibitors, aging preventive (or ameliorating) agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Animal Husbandry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)結晶子径が1μm未満の該シリコン微細粒子及び該シリコン微細粒子の凝集体の、全ての該シリコン粒子、該シリコン微細粒子及びそれらの該凝集体に対する割合が、5質量%以下であること。
(2)前記シリコン粒子の表面又は該シリコン微細粒子の表面の少なくとも一部に担持している、付着している、又は吸着している、あるいは該表面と化学結合している、生理学的に許容可能な又は医学的に許容可能な金属(以下、総称して、「生理学的に許容可能な金属」という。)、より具体的には鉄(Fe)又は鉄(Fe)含有物質(以下、総称して「鉄(Fe)」という。)、を備えること。
(a)発生総量(生成総量)を高めること
(b)単位時間当たりの水素発生量(すなわち、水素の発生速度)の中でも特に初期段階における水素の発生速度を高めること
(c)経口摂取した場合に、シリコン粒子が直接的に吸収され血管に浸入することを確度高く防止し得ること
(1)皮膚疾患
(2)皮膚のかゆみ
(3)便秘症又は下痢症
(4)二日酔い症候群(hangover syndrome)
(5)ヒトの老化予防又は改善
<第1の実施形態>
本実施形態の酸化ストレス抑制剤100、及び酸化ストレス抑制剤100の製造方法について詳述する。図1(a)は、本実施形態の酸化ストレス抑制剤100の模式図である。図1(a)に示すように、本実施形態の酸化ストレス抑制剤100は、水素発生能を有する、シリコン粒子又はシリコン微細粒子(以下、総称して「シリコン粒子」という。)10とを備える。
次に、本実施形態の酸化ストレス抑制剤100の製造方法を説明する。また、酸化ストレス抑制剤100と水含有液との反応過程において測定又は観察された酸化ストレス抑制剤100の表面、及び該表面を覆う酸化シリコン膜について説明する。
本実施形態においては、例えば市販の高純度シリコン粒子粉末(粒径300μm以下,純度99.999%,i型シリコン)を、酸化ストレス抑制剤100の原料の一部として用いる。なお、本実施形態の他の一態様においては、前述の純度よりも高純度、又は低純度のシリコン粒子粉末を採用することができる。
本実施形態の粉砕工程(第1粉砕工程又は第2粉砕工程)と、後述する金属元素の担持工程との間に、分級工程が行われることも本実施形態の一態様である。具体的には、結晶子径が1μm未満のシリコン微細粒子10及びシリコン微細粒子10の凝集体の、全てのシリコン粒子10、シリコン微細粒子10及びそれらの該凝集体に対する割合が、5質量%以下(より好適には3質量%以下、さらに好適には1質量%以下、さらに好適には0.5質量%以下、さらに好適には0.2質量%以下)となるように、気流法を用いて、1μm未満の結晶子径のシリコン微細粒子10及びシリコン微細粒子10の凝集体がほぼ除去される。なお、シリコン粒子10に対して「結晶子径」という用語を採用するのとは異なり、シリコン粒子10の凝集体に対しては、その全体の径を表す用語として「結晶粒径」を用いる。
本変形例の酸化ストレス抑制剤200、及び酸化ストレス抑制剤200の製造方法について詳述する。図1(b)は、本変形例の酸化ストレス抑制剤200の模式図である。図1(b)に示すように、本変形例の酸化ストレス抑制剤200は、水素発生能を有する、シリコン粒子又はシリコン微細粒子(以下、総称して「シリコン粒子」という。)10と、シリコン粒子10の表面又はシリコン微細粒子10の表面の少なくとも一部に担持、付着、又は吸着している、又は該表面と化学結合している、生理学的に許容可能な金属元素20と、を備える。
<金属元素の担持工程>
本変形例の酸化ストレス抑制剤200の製造方法においては、第1の実施形態の酸化ストレス抑制剤100の製造方法に対して、さらに、シリコン粒子10の表面又はシリコン微細粒子10の表面に金属元素20を担持、付着、又は吸着させる工程、又は金属元素20とシリコン粒子10の表面とを化学結合させる化学結合工程(以下、総称して「担持工程」という。)が行われる。
その後、本発明者は、水含有液と酸化ストレス抑制剤200とを接触させる接触工程を行うことによる水素(H2)の発生総量(生成総量)及び水素の発生速度(生成速度)を分析するため、酸化ストレス抑制剤200をpH調整剤として炭酸水素ナトリウムを溶質とする水溶液であって、ヒトの体温相当の温度(37℃)の水含有液(pH値は8.2)に浸漬させた。
以下、第1の実施形態をより詳細に説明するために、実施例を挙げて説明するが、第1の実施形態はこれらの例によって限定されるものではない。
実施例1は、シリコン粒子10の表面又はシリコン微細粒子10の表面の一部が金属元素20を担持している、又は該表面と金属元素20とが化学結合している酸化ストレス抑制剤200である。なお、実施例1の金属元素20は鉄(Fe)である。また、実施例1における質量比については、シリコン粒子10に対する金属元素20が、約10ppmwである。
実施例2も、実施例1と同様に、シリコン粒子10の表面又はシリコン微細粒子10の表面の一部が金属元素20を担持している、又は該表面と金属元素20とが化学結合している酸化ストレス抑制剤200である。なお、実施例2の金属元素20は鉄(Fe)である。また、実施例2における質量比については、シリコン粒子10に対する金属元素20が、約5ppmwである。
さらに、本発明者は、透過型電子顕微鏡(TEM)を用いて、上述の実施例1の酸化ストレス抑制剤200と上述の水含有液との反応、及び上述の比較例のシリコン粒子と上述の水含有液との反応によって形成された該表面を覆う酸化シリコン膜を分析した。図3は、上述の実施例1の酸化ストレス抑制剤(a)及び比較例(b)の、各酸化シリコンの膜厚を示す断面TEM像である。
上述の第1の実施形態において粉砕工程が行われた後、あるいは、第1の実施形態の変形例(1)において粉砕工程が行われた後であって担持工程が行われる前に、シリコン粒子10の表面又はシリコン微細粒子10の表面を、さらに、過酸化水素水に接触させることにより、該表面の改質を行う改質工程を行うことも好適な一態様である。この改質工程によって、シリコンナノ粒子を含むシリコン粒子は、巨視的に見たときに、親水性にすることが可能となる。例えば、公知の容器中に収容した過酸化水素水(例えば、約10℃~約80℃、より低コストを実現する観点では約20℃~約50℃)の中に、該シリコン粒子を浸漬させることによって、改質工程を行うことができる。
また、本変形例においては、第1の実施形態又は第1の実施形態の変形例(1)、(2)の酸化ストレス抑制剤100,200の500mgを、炭酸水素ナトリウム粉末(和光純薬株式会社製、純度99.5%)約500mgと混合する。この混合物を混錬し、打錠法を用いて、直径約8mm、高さ約4mmの円柱型の塊状体としての錠剤(例えば、医薬用又は医薬部外品用の錠剤)を得ることができる。なお、錠剤は、塊状製剤の一例である。また、安定なシリコンサブオキサイドを有する酸化ストレス抑制剤100,200及び炭酸水素ナトリウム等のpH調整剤を別々に酸性下では溶解せず、塩基性下では溶解する、ナノカプセル、マイクロカプセル、通常のカプセル、又はコーティングを行うことは、好適な一態様である。前述の態様を採用することにより、酸性条件における水分の存在下での反応を回避して、塩基性で水分の存在下において、溶解して酸化ストレス抑制剤100,200と水とが反応することを促すことが可能となる。
なお、上述の第1の実施形態又は第1の実施形態の変形例(1)~(3)の酸化ストレス抑制剤100,200は、例えば、製剤(医薬用)又は医薬部外品として活用することができる。加えて、その活用例は、錠剤に限定されない。例えば、錠剤の代わりに、粉状の酸化ストレス抑制剤100,200をカプセルに内包させたカプセル剤を採用した場合であっても、上述の効果と同様の効果が奏され得る。酸化ストレス抑制剤100,200は、塊状でなく表面積の大きな粉状である方が多くの水素を発生させ得るが、錠剤又はカプセル剤にすることより、経口摂取、あるいは、肛門からの摂取が容易になる。また、錠剤又はカプセル剤にすることにより、胃内ではある程度、塊状を保つ一方、胃を通過した後は崩壊が進み粉状を呈するようになる。このため水素発生反応を抑制したい胃内においては、酸化ストレス抑制剤100,200が胃液及び/又は胃の内容物に曝される表面積を少なくし、水素発生反応を促進したい小腸及び/又は大腸において水含有液に曝される表面積を多くすることができる。
また、上述の第1の実施形態又は第1の実施形態の変形例(1)~(4)の酸化ストレス抑制剤100,200は、例えば、酸化ストレス抑制剤100,200に接触させる「媒体」を用いることにより、経皮的又は経粘膜的に水素を体内(皮膚自身又は粘膜自身を含む)に取り込むことが可能となる。なお、本変形例の媒体は、特に材料又は商品を限定しない。生理学的に許容可能な媒体であれば、本変形例の効果を奏し得る。従って、酸化ストレス抑制剤100,200と、酸化ストレス抑制剤100,200に接する該媒体とを備えるものは、水素供給材としての機能を発揮し得る。
[実施例3]
[皮膚疾患に対する酸化ストレス抑制剤の効果]
図4は、酸化ストレス抑制剤の効果確認の試験者の、(a)酸化ストレス抑制剤摂取前の手のひらの状況を示す写真と、(b)酸化ストレス抑制剤を摂取してから5日後の手のひらの状況を示す写真である。
[便秘症又は下痢症に対する酸化ストレス抑制剤の効果]
本実施例においては、便通の頻度が低い便秘症、あるいは下痢症の疾患を持つ、自分の意志で本実施例に参加した試験者(便秘症:20代女性,40代女性,60代女性)が、毎日、酸化ストレス抑制剤100を1g/日を経口摂取した。そして、酸化ストレス抑制剤の摂取開始から5日後の、該試験者の便通の改善の有無、及び/又は健康な排便回数を確認したところ、いずれの症状も改善効果が見られた。
[二日酔い症候群に対する酸化ストレス抑制剤の効果]
本実施例においては、二日酔い症候群(「二日酔い」と称される一連の生理的な症候)の、自分の意志で本実施例に参加した試験者(30代男性、40代男性、50代男性、60代男性)が、毎日、酸化ストレス抑制剤100を1g/日を経口摂取した。そして、酸化ストレス抑制剤の摂取開始から2日以上経過した後の、該試験者の二日酔いの症候の改善の有無を確認したところ、改善効果が見られた。なお、「二日酔い症候群」には、吐き気、嘔吐、頭痛、眠気、運動能力低下の各現象を含む。また、アルコール摂取時、又はその後に体内で生成されるアセトアルデヒドが、二日酔い症候群の原因であることは良く知られている。
ところで、上述の第1の実施形態又は第1の実施形態の各変形例の酸化ストレス抑制剤100,200は、ヒト用のサプリメントや食品添加物としても利用することができる。従って、上述の第1の実施形態又は第1の実施形態の各変形例の酸化ストレス抑制剤100,200を含む食品は、採用し得る好適な一態様である。
また、上述の第1の実施形態又は第1の実施形態の各変形例の酸化ストレス抑制剤100,200は、自然な状態において凝集することによってμmレベル(例えば、数十μm以上)の径の大きさの凝集体を構成し得る。この凝集体又は結合剤の添加や圧縮等により、人為的に酸化ストレス抑制剤100,200を集合させることによって、ヒトの指によってつまめる程度の大きさの塊状の固体の製剤とした配合物を形成することができる。
ところで、上述の第1の実施形態又は第1の実施形態の各変形例の酸化ストレス抑制剤100,200について、例えば、最初の接触工程(第1接触工程)においてpH値が7未満の第1水含有液に接触させ、その後の接触工程(第2接触工程)においてpH値が7以上の第2水含有液と接触させ、第2接触工程で水素を発生させることができる。なお、上述の各実施形態の酸化ストレス抑制剤100,200は、pH値が7以上(より好適には7超、さらに好適には8.2以上)の水含有液に接触したときに著しい水素発生能を有し得る。
(1)皮膚疾患
(2)皮膚のかゆみ
(3)便秘症又は下痢症
(4)二日酔い症候群(hangover syndrome)
(5)ヒトの老化予防又は改善
従って、上述の第1の実施形態又は第1の実施形態の各変形例から導かれる他の技術思想は、既に説明した各技術思想に加えて、少なくとも以下の(A)~(F)を含む。
(A)水素発生能を有するシリコン粒子及びシリコン微細粒子を含む、抗酸化剤
(B)前述の(A)において、結晶子径が1μm未満の該シリコン微細粒子及び該シリコン微細粒子の凝集体の、全ての該シリコン粒子、該シリコン微細粒子及びそれらの該凝集体に対する割合が、5質量%以下である、抗酸化剤
(C)前述の(A)又は(B)において、該シリコン粒子の表面又は該シリコン微細粒子の表面の少なくとも一部に担持している、付着している、又は吸着している、あるいは該表面と化学結合している、生理学的に許容可能な又は医学的に許容可能な金属元素(鉄(Fe))、を備える、抗酸化剤
(D)水素発生能を有するシリコン粒子及びシリコン微細粒子を含む、ヒドロキシルラジカル抑制剤
(E)前述の(D)において、結晶子径が1μm未満の該シリコン微細粒子及び該シリコン微細粒子の凝集体の、全ての該シリコン粒子、該シリコン微細粒子及びそれらの該凝集体に対する割合が、5質量%以下である、ヒドロキシルラジカル抑制剤
(F)前述の(D)又は(E)において、該シリコン粒子の表面又は該シリコン微細粒子の表面の少なくとも一部に担持している、付着している、又は吸着している、あるいは該表面と化学結合している、生理学的に許容可能な又は医学的に許容可能な金属元素(鉄(Fe))、を備える、ヒドロキシルラジカル抑制剤
また、上述の第1の実施形態又は第1の実施形態の各変形例から導かれる各技術思想、並びに上述のその他の実施形態(4)の(A)~(F)において開示した技術思想に加えて、該酸化ストレス抑制剤、該抗酸化剤、及び/又は該ヒドロキシルラジカル抑制剤(本実施形態においては、以下、総称して「抗酸化剤」という。)は、抗体医薬の製造方法においても活用され得る。従って、本実施形態においては、抗体医薬の製造方法の各工程においては、上述の各技術思想に基づく、水素発生能を有するシリコン粒子及びシリコン微細粒子を含む抗酸化剤が用いられ得る。
(I)非ヒト動物、ヒト(倫理的に承認又は許容されたものに限る。以下、同じ)、植物、菌類(大腸菌等)、又は各種の卵の抗体産生細胞及び/又は形質細胞の調製工程
(II)前記抗体産生細胞及び/又は前記形質細胞の分離工程
(III)ハイブリドーマ細胞を生産するハイブリドーマ細胞生産工程
(IV)モノクローナル抗体を生産するモノクローナル抗体生産工程
また、上述の第1の実施形態又は第1の実施形態の各変形例から導かれる各技術思想、並びに上述のその他の実施形態(4)の(A)~(F)において開示した技術思想に加えて、該酸化ストレス抑制剤、該抗酸化剤、及び/又は該ヒドロキシルラジカル抑制剤(本実施形態においては、以下、総称して「抗酸化剤」という。)は、体外受精・胚移植法における細胞の培養、あるいはES細胞、iPS細胞(induced pluripotent stem cells)及び体性幹細胞の群から選択される少なくとも1種の細胞の培養を行うときも活用され得る。
20 金属元素
100,200 酸化ストレス抑制剤,抗酸化剤,ヒドロキシルラジカル抑制剤,老化の予防(又は改善)剤
Claims (14)
- 水素発生能を有するシリコン粒子及びシリコン微細粒子を含む、
酸化ストレス抑制剤。 - 結晶子径が1μm未満の該シリコン微細粒子及び該シリコン微細粒子の凝集体の、全ての該シリコン粒子、該シリコン微細粒子及びそれらの該凝集体に対する割合が、5質量%以下である、
請求項1に記載の酸化ストレス抑制剤。 - 前記シリコン粒子の表面又は該シリコン微細粒子の表面の少なくとも一部に担持している、付着している、又は吸着している、あるいは該表面と化学結合している鉄(Fe)を備える、
請求項1又は請求項2に記載の酸化ストレス抑制剤。 - 前記シリコン粒子又は前記シリコン微細粒子を1としたときの前記鉄(Fe)の質量比が、0.1ppmw以上1000ppmw以下である、
請求項3に記載の酸化ストレス抑制剤。 - 前記シリコン粒子又は前記シリコン微細粒子を1としたときの前記鉄(Fe)の質量比が、0.5ppmw以上1000ppmw以下である、
請求項3に記載の酸化ストレス抑制剤。 - 請求項1乃至請求項5のいずれか1項に記載の酸化ストレス抑制剤を含有する、
サプリメント。 - 請求項1乃至請求項5のいずれか1項に記載の酸化ストレス抑制剤を含有する、
皮膚疾患の予防または改善用サプリメント。 - 前記皮膚疾患が、湿疹、炎症性皮膚疾患、皮膚バリア機能障害アレルギー性皮膚炎、及びアトピー性皮膚炎の群から選択される少なくとも1種である、
請求項7に記載の皮膚疾患の予防または改善用サプリメント。 - 請求項1乃至請求項5のいずれか1項に記載の酸化ストレス抑制剤を含有する、
便秘症、下痢症、又は二日酔い症候群(hangover syndrome)の予防または改善用サプリメント。 - 請求項1乃至請求項5のいずれか1項に記載の酸化ストレス抑制剤を含有する、
老化の予防または改善用サプリメント。 - 請求項1乃至請求項5のいずれか1項に記載の酸化ストレス抑制剤を含有する、
食品。 - 水素発生能を有するシリコン粒子及びシリコン微細粒子を含む、
抗酸化剤。 - 結晶子径が1μm未満の該シリコン微細粒子及び該シリコン微細粒子の凝集体の、全ての該シリコン粒子、該シリコン微細粒子及びそれらの該凝集体に対する割合が、5質量%以下である、
請求項12に記載の抗酸化剤。 - 前記シリコン粒子の表面又は該シリコン微細粒子の表面の少なくとも一部に担持している、付着している、又は吸着している、あるいは該表面と化学結合している鉄(Fe)を備える、
請求項12又は請求項13に記載の抗酸化剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21780780.9A EP4129306A4 (en) | 2020-04-02 | 2021-03-02 | OXIDATIVE STRESS INHIBITORS AND ANTIOXIDANTS |
CA3174295A CA3174295A1 (en) | 2020-04-02 | 2021-03-02 | Oxidative stress inhibitor and antioxidant agent |
CN202180023224.2A CN115443139A (zh) | 2020-04-02 | 2021-03-02 | 氧化应激抑制剂和抗氧化剂 |
JP2021526647A JP6924918B1 (ja) | 2020-04-02 | 2021-03-02 | 酸化ストレス抑制剤及び抗酸化剤 |
US17/995,226 US20230149445A1 (en) | 2020-04-02 | 2021-03-02 | Oxidative stress inhibitor and antioxidant agent |
TW110124515A TW202228732A (zh) | 2021-01-29 | 2021-07-02 | 氧化壓力抑制劑及抗氧化劑 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-067000 | 2020-04-02 | ||
JP2020-066999 | 2020-04-02 | ||
JP2020066999 | 2020-04-02 | ||
JP2020067000 | 2020-04-02 | ||
PCT/JP2021/003383 WO2021199644A1 (ja) | 2020-04-02 | 2021-01-29 | 複合材 |
JPPCT/JP2021/003383 | 2021-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021199850A1 true WO2021199850A1 (ja) | 2021-10-07 |
Family
ID=77929587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/007917 WO2021199850A1 (ja) | 2020-04-02 | 2021-03-02 | 酸化ストレス抑制剤及び抗酸化剤 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4129306A4 (ja) |
WO (1) | WO2021199850A1 (ja) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011058317A1 (en) * | 2009-11-12 | 2011-05-19 | Isis Innovation Limited | Preparation of silicon for fast generation of hydrogen through reaction with water |
JP5514140B2 (ja) | 2011-04-04 | 2014-06-04 | 株式会社日省エンジニアリング | ポット型飲料用水素水の生成器 |
JP2015113331A (ja) | 2013-12-16 | 2015-06-22 | 株式会社光未来 | 水素含有組成物および該水素含有組成物を用いた水素の添加方法 |
WO2017130709A1 (ja) | 2016-01-29 | 2017-08-03 | 小林 光 | 固形製剤、固形製剤の製造方法及び水素発生方法 |
WO2018037752A1 (ja) | 2015-02-24 | 2018-03-01 | 小林 光 | 水素含有液、水素含有液の製造方法、及び水素含有液の製造装置、並びに生体用水素発生材 |
WO2018037819A1 (ja) | 2016-08-23 | 2018-03-01 | 小林 光 | 配合物及びその製造方法、並びに水素供給方法 |
WO2018037818A1 (ja) | 2016-08-23 | 2018-03-01 | 小林 光 | 水素供給材及びその製造方法、並びに水素供給方法 |
WO2019021769A1 (ja) * | 2017-07-27 | 2019-01-31 | 国立大学法人大阪大学 | 薬剤及びその製造方法 |
WO2019211960A1 (ja) | 2018-04-29 | 2019-11-07 | 株式会社Kit | 複合組成物 |
WO2019235577A1 (ja) * | 2018-06-07 | 2019-12-12 | 国立大学法人大阪大学 | 酸化ストレスに起因する疾患の予防又は治療剤 |
JP2019214556A (ja) * | 2018-06-07 | 2019-12-19 | 国立大学法人大阪大学 | 酸化ストレスに起因する疾患の予防又は治療剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101953449B1 (ko) * | 2014-05-29 | 2019-02-28 | 가부시키가이샤 도요다 지도숏키 | 실리콘 재료 및 이차 전지의 부극 |
-
2021
- 2021-03-02 EP EP21780780.9A patent/EP4129306A4/en active Pending
- 2021-03-02 WO PCT/JP2021/007917 patent/WO2021199850A1/ja unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011058317A1 (en) * | 2009-11-12 | 2011-05-19 | Isis Innovation Limited | Preparation of silicon for fast generation of hydrogen through reaction with water |
JP5514140B2 (ja) | 2011-04-04 | 2014-06-04 | 株式会社日省エンジニアリング | ポット型飲料用水素水の生成器 |
JP2015113331A (ja) | 2013-12-16 | 2015-06-22 | 株式会社光未来 | 水素含有組成物および該水素含有組成物を用いた水素の添加方法 |
WO2018037752A1 (ja) | 2015-02-24 | 2018-03-01 | 小林 光 | 水素含有液、水素含有液の製造方法、及び水素含有液の製造装置、並びに生体用水素発生材 |
WO2017130709A1 (ja) | 2016-01-29 | 2017-08-03 | 小林 光 | 固形製剤、固形製剤の製造方法及び水素発生方法 |
WO2018037819A1 (ja) | 2016-08-23 | 2018-03-01 | 小林 光 | 配合物及びその製造方法、並びに水素供給方法 |
WO2018037818A1 (ja) | 2016-08-23 | 2018-03-01 | 小林 光 | 水素供給材及びその製造方法、並びに水素供給方法 |
WO2019021769A1 (ja) * | 2017-07-27 | 2019-01-31 | 国立大学法人大阪大学 | 薬剤及びその製造方法 |
WO2019211960A1 (ja) | 2018-04-29 | 2019-11-07 | 株式会社Kit | 複合組成物 |
WO2019235577A1 (ja) * | 2018-06-07 | 2019-12-12 | 国立大学法人大阪大学 | 酸化ストレスに起因する疾患の予防又は治療剤 |
JP2019214556A (ja) * | 2018-06-07 | 2019-12-19 | 国立大学法人大阪大学 | 酸化ストレスに起因する疾患の予防又は治療剤 |
Non-Patent Citations (4)
Title |
---|
FUJINOE ET AL.: "Generation of hydrogen by reaction of silicon nanoparticles with neutral region", EXTENDED ABSTRACTS OF THE 64TH JSAP SPRING MEETING, 2015, pages 421 - 6 |
MATSUDA ET AL.: "Water decomposition due to silicon nanoparticles and hydrogen concentrations", EXTENDED ABSTRACTS OF THE 62ND JSAP SPRING MEETING, 2015, pages 12 - 031 |
OTANI NAOYA, TOMITA KOICHI, KOBAYASHI YUKI, KURODA KAZUYA, KOYAMA YOSHIHISA, KOBAYASHI HIKARU, KUBO TATEKI: "Hydrogen-generating Si-based agent protects against skin flap ischemia–reperfusion injury in rats", SCIENTIFIC REPORTS, vol. 12, no. 6168, 13 April 2022 (2022-04-13), pages 1 - 8, XP055935543, DOI: 10.1038/s41598-022-10228-6 * |
See also references of EP4129306A4 |
Also Published As
Publication number | Publication date |
---|---|
EP4129306A4 (en) | 2024-08-28 |
EP4129306A1 (en) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11951125B2 (en) | Drug and production method therefor | |
TWI818972B (zh) | 複合組成物 | |
JP2024040386A (ja) | 薬剤及びその製造方法 | |
JP6924918B1 (ja) | 酸化ストレス抑制剤及び抗酸化剤 | |
WO2021199850A1 (ja) | 酸化ストレス抑制剤及び抗酸化剤 | |
JP7461005B2 (ja) | 自閉スペクトラム症の予防又は治療剤 | |
JP7461010B2 (ja) | 虚血性脳血管障害に伴う障害の予防又は治療剤 | |
JP7461007B2 (ja) | 内臓不快感の予防又は治療剤 | |
JP7461003B2 (ja) | パーキンソン病の予防又は治療剤 | |
JP2021165269A (ja) | 酸化ストレス抑制剤及び抗酸化剤 | |
JP2013526614A (ja) | 水銀毒性の低減のための組成物及び方法 | |
JP2020117480A (ja) | 記憶障害の予防又は治療剤 | |
JP2020117484A (ja) | 脊髄損傷後の障害もしくは症状の予防又は治療剤 | |
JP2020007300A (ja) | うつ病又はうつ状態の予防又は治療剤 | |
TW202228732A (zh) | 氧化壓力抑制劑及抗氧化劑 | |
WO2021199792A1 (ja) | 肺炎の予防または治療用製剤 | |
WO2021199644A1 (ja) | 複合材 | |
WO2021206020A1 (ja) | 注意欠陥多動性障害の予防又は治療剤 | |
WO2022201775A1 (ja) | 腸内細菌数低減剤 | |
US20230365415A1 (en) | Composite material | |
US20240269165A1 (en) | Fine silicon particle-containing preventive or therapeutic agent for diseases | |
JP2006169184A (ja) | 遠赤外線を発する黒鉛珪石微粒子コロイド水の製造方法 | |
EP4104852A1 (en) | Composition with immunostimulating and immunoregulating activity to promote the immune response of the human organism | |
Riedle | Dietary titanium dioxide particles and intestinal health: a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science at Massey University, Manawatū, New Zealand. | |
JPH03127739A (ja) | アルコール吸収抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2021526647 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21780780 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3174295 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021780780 Country of ref document: EP Effective date: 20221102 |